Neoplasms

Symptoms and General Pathology

All Conditions

Blood and Lymph Conditions

Rare Diseases

Neoplasm Metastasis

Syndrome

Leukemia

Leukemia, Myeloid

Leukemia, Myeloid, Acute

Preleukemia

Myelodysplastic Syndromes

Hematologic Diseases

Neoplasms by Histologic Type

Bone Marrow Diseases

Precancerous Conditions

Myeloid Leukemia

Acute Myeloid Leukemia

Acute Non Lymphoblastic Leukemia

Acute Graft Versus Host Disease

Antineoplastic Agents

All Drugs and Chemicals

Anti-Infective Agents

Analgesics

Etoposide

Cytarabine

Mitoxantrone

Daunorubicin

Etoposide phosphate

Idarubicin

Ivosidenib

Enzyme Inhibitors

Antimetabolites

Antiviral Agents

Immunosuppressive Agents

Immunologic Factors

Anti-Bacterial Agents

Antibiotics, Antitubercular

Daily AG-120 administered orally in combination with standard Induction therapy and consolidation therapy. After 1 cycle of induction therapy, participants may undergo a second induction cycle given as per institutional practice. Participants who achieve an adequate response at the end of induction therapy will go on to receive consolidation therapy (mitoxantrone/etoposide or up to 4 cycles of cytarabine) in combination with AG-120. Participants who complete consolidation therapy and are in complete response (CR) or complete remission with incomplete hematologic recovery (CRi) (including CR with incomplete platelet recovery \[CRp\]) may continue on maintenance therapy and receive daily treatment with AG-120.

Daily AG-120 administered orally in combination with standard Induction therapy and consolidation therapy. After 1 cycle of induction therapy, participants may undergo a second induction cycle given as per institutional practice. Participants who achieve an adequate response at the end of induction therapy will go on to receive consolidation therapy (mitoxantrone/etoposide or up to 4 cycles of cytarabine) in combination with AG-120. Participants who complete consolidation therapy and are in CR or CRi (including CRp) may continue on maintenance therapy and receive daily treatment with AG-120.

Daily AG-221 administered orally in combination with standard Induction therapy and consolidation therapy. After 1 cycle of induction therapy, participants may undergo a second induction cycle given as per institutional practice. Participants who achieve an adequate response at the end of induction therapy will go on to receive consolidation therapy (mitoxantrone/etoposide or up to 4 cycles of cytarabine) in combination with AG-221. Participants who complete consolidation therapy and are in CR or CRi (including CRp) may continue on maintenance therapy and receive daily treatment with AG-221.

Daily AG-221 administered orally starting on Day 8 of induction cycle 1 in combination with standard Induction therapy and consolidation therapy. After 1 cycle of induction therapy, participants may undergo a second induction cycle given as per institutional practice. Participants who achieve an adequate response at the end of induction therapy will go on to receive consolidation therapy (mitoxantrone/etoposide or up to 4 cycles of cytarabine) in combination with AG-221. Participants who complete consolidation therapy and are in CR or CRi (including CRp) may continue on maintenance therapy and receive daily treatment with AG-221.

AG-120

AG-221

cytarabine

daunorubicin

idarubicin

mitoxantrone

etoposide

The purpose of this Phase I, multicenter, clinical trial is to evaluate the safety of AG-120 and AG-221 when given in combination with standard AML induction and consolidation therapy. The study plans to evaluate up to 2 dose levels of AG-120 in participants with an isocitrate dehydrogenase protein 1 (IDH1) mutation and up to 2 dose levels of AG-221 in participants with an isocitrate dehydrogenase protein 2 (IDH2) mutation. AG-120 or AG-221 will be administered with 2 types of AML induction therapies (cytarabine with either daunorubicin or idarubicin) and 2 types of AML consolidation therapies (mitoxantrone with etoposide \[ME\] or cytarabine). After consolidation therapy, participants may continue on to maintenance therapy and receive daily treatment with single-agent AG-120 or AG-221 until relapse, development of an unacceptable toxicity, or hematopoietic stem cell transplant (HSCT). The study will end when all participants have discontinued study treatment.

Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination With Induction Therapy and Consolidation Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia With an IDH1 and/or IDH2 Mutation

Qualified scientific and medical researchers can request access to anonymized patient-level and study-level clinical trial data.

Access can be requested for all interventional clinical studies:

* used for Marketing Authorization (MA) of medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).
* where Servier is the Marketing Authorization Holder (MAH). The date of the first MA of the new medicine (or the new indication) in one of the EEA Member States will be considered for this scope.

In addition, access can be requested for all interventional clinical studies in patients:

* sponsored by Servier
* with a first patient enrolled as of 1 January 2004 onwards
* for New Chemical Entity or New Biological Entity (new pharmaceutical form excluded) for which development has been terminated before any Marketing authorization (MA) approval.

An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related.

Descriptive statistics will be used to summarize PK parameters for each dose group and, where appropriate, for the entire population.

Celgene Corporation

Institut de Recherches Internationales Servier

Nervous System Diseases

Heart and Blood Diseases

Wounds and Injuries

Hematoma, Subdural

Neoplastic Processes

Amino Acids

Bevacizumab

Erlotinib Hydrochloride

Antineoplastic Agents, Immunological

Angiogenesis Inhibitors

Growth Inhibitors

Tyrosine Kinase Inhibitors

Protein Kinase Inhibitors

Tyrosine

Patients will receive bevacizumab 10 mg/kg IV over 30-90 minutes every 2 weeks until disease progression or unacceptable toxicity.

bevacizumab

Patients will receive elrotinib 150 mg orally once a day continuously until disease progression or unacceptable toxicity.

erlotinib

Inkeun Park, M.D, Ph.D

Hye-won Ryu

Beo-Deul Kang

Jee Hyun Kim

Jung Hoon Kang

Joo-Hwan Park

Ju Won Kim

Min-Kyu Jung

Inkeun Park

Se-Jun Park

Hyeon-Su Im

A national, prospective, multi-center, open-label, single arm phase II trial investigating the efficacy and safety of bevacizumab plus erlotinib in patients with advanced cancers which harbors genomic alterations in Krebs cycle

The BRISK study will recruit patients with locally advanced or metastatic solid tumor harboring the genomic alterations in Krebs cycle (e.g. fumarate hydratase, isocitrate dehydrogenase, succinate dehydrogenase) who had disease progression on standard systemic treatment and/or has no standard treatment option, and investigate the efficacy and safety of bevacizumab plus erlotinib.

A Phase II Stydy of Bevacizumab Plus Erlotinib in Patients for Krebs Cycle Altered Cancer

A Phase II Clinical Trial of Bevacizumab Plus eRlotinIb in patientS With Advanced Cancer Having Genetic Alterations in Krebs Cycle (BRISK, KCSG AL22-16)

Defined as a proportion of complete response (CR) + partial response (PR) according to RECIST v1.1, the fraction with a response (CR+PR) will be reported separately by cohort, along with a 95% confidence interval

Assessed according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, PFS will be determined using the Kaplan-Meier method, and the curves presented along with a 95% confidence interval on the median PFS

The Kaplan-Meier method will be used and the curves presented along with a 95% confidence interval on the median OS

Severity of adverse events will be graded by NCI-CTCAE (National Cancer Institute - Common Terminology Criteria for Adverse Events) v5.0

Korean Cancer Study Group

Boryung Pharmaceutical Co., Ltd

Asan Medical Center

Clinical Associate Professor

Fludarabine

Fludarabine phosphate

Azacitidine

Patients will receive HMPL-306 monotherapy: HMPL-306 PO at 250 mg QD (C1) + 150 mg QD (starting from C2), 28 days as a cycle.

HMPL-306 Regimen

Patients in this regimen will receive treatment with one of the following regimens, and the regimen will be selected by the investigator based on the patient's condition:

* MEC regimen: etoposide injection 100 mg/m2, cytarabine injection 1000 mg/m2, mitoxantrone injection 8 mg/m2 QD IV for 5 consecutive days (Days 1-5).
* FLAG ± Ida regimen: G-CSF injection 300 mcg/m2 QD SC for 5 consecutive days (Days 1-5); fludarabine injection 30 mg/m2 QD IV for 5 consecutive days (Days 2-6); cytarabine injection 2000 mg/m2 QD IV for 5 consecutive days (Days 2-6); idarubicin injection 10 mg/m2 QD IV for 3 consecutive days (Days 2-4).
* LoDAC: cytarabine injection 20 mg q12h SC or IV for 10 consecutive days (Days 1-10).
* Azacitidine: azacitidine injection 75 mg/m2 QD SC or IV for 7 consecutive days (Days 1-7).

Salvage Chemotherapy Regimen

Jian Chen, Doctor

Zeyang Zhou, Master

Xiaojun Huang, Doctor

An open-label design is adopted in this study. All patients will first undergo pre-screening to determine the mutation status of IDH, and all patients will be assigned to the registry study of the corresponding cohorts of IDH1 and IDH2 based on the pre-screening results. Patients with both IDH1 and IDH2 mutations will be enrolled in the IDH2 cohort. This study is divided into two cohorts. Cohort 1 includes R/R AML patients with IDH1-R132 mutations; Cohort 2 includes R/R AML patients with IDH2-R140 and R172 mutations. The two cohorts are designed independently and will be analyzed separately for statistical hypothesis testing. Patients in both cohorts will be randomized in a 1:1 ratio according to the central Interactive Web Response System (IWRS) into the test or control group, patients in the test group will receive HMPL-306 monotherapy at a dose of 250 mg once daily (QD) (Cycle 1, C1) + 150 mg QD \[starting from Cycle 2 (C2)\]. Patients in the control group will receive salvage chemotherapy (one of four options) consisting of two intensive chemotherapy regimens (MEC regimen and FLAG ± Ida regimen) and two non-intensive chemotherapy regimens (azacitidine and LoDAC)

Study overview This is a multicenter, randomized, open-label phase III clinical study to evaluate the efficacy, safety, and pharmacokinetic (PK) of HMPL-306 vs. salvage chemotherapy in patients with IDH1- and IDH2-mutated R/R AML.

An open-label design is adopted in this study. All patients will first undergo pre-screening to determine the mutation status of IDH, and all patients will be assigned to the registry study of the corresponding cohorts of IDH1 and IDH2 based on the pre-screening results. Patients with both IDH1 and IDH2 mutations will be enrolled in the IDH2 cohort. This study is divided into two cohorts. Cohort 1 includes R/R AML patients with IDH1-R132 mutations; Cohort 2 includes R/R AML patients with IDH2-R140 and R172 mutations. The two cohorts are designed independently and will be analyzed separately for statistical hypothesis testing. Patients in both cohorts will be randomized in a 1:1 ratio according to the central Interactive Web Response System (IWRS) into the test or control group, patients in the test group will receive HMPL-306 monotherapy at a dose of 250 mg once daily (QD) (Cycle 1, C1) + 150 mg QD \[starting from Cycle 2 (C2)\]. Patients in the control group will receive salvage chemotherapy (one of four options) consisting of two intensive chemotherapy regimens (MEC regimen and FLAG ± Ida regimen) and two non-intensive chemotherapy regimens (azacitidine and LoDAC). Before randomization, the investigator will preselect a salvage chemotherapy regimen based on the patient's condition. Patients will then be stratified and randomized based on their prior first-line treatment response (recurrence within 6 months after allogeneic Hematopoietic stem cell transplantation (HSCT), recurrence beyond 6 months after allogeneic HSCT, primary refractory disease without HSCT, recurrence within 6 months after achieving CR/CRh without HSCT, recurrence beyond 6 months after achieving complete response (CR)/CR with partial hematologic recovery (CRh) without HSCT) and the intensity of preselected chemotherapy regimen (intensive chemotherapy, non-intensive chemotherapy).

After the patient signs the pre-screening informed consent form (ICF), pre-screening (genetic testing) will be performed to determine the mutation status of IDH, so as to clarify the subsequent enrollment of the cohorts. Patients who meet the inclusion criteria will receive treatment in the test group or the control group. Each treatment cycle lasts for 28 days. Treatment will continue until progression of disease (PD)/recurrence, death, intolerable toxicity, initiation of a new anti-tumor therapy, the patient no longer benefits from the treatment as judged by the investigator, the patient or his/her legal representative requests to withdraw from the study, loss to follow-up, or end of study, whichever occurs first (the treatment cycle of MEC regimen and FLAG ± Ida regimen in the chemotherapy group will be adjusted based on the actual dosing, and a maximum of two treatment cycles is allowed).

Patients with PD in the control group should not be crossed over to the test group, and patients in the control group should not be crossed over to other salvage treatment regimens.

The information of treatment groups is as follows (consistent between the two cohorts):

* Test group: Patients will receive HMPL-306 monotherapy:

  - HMPL-306 PO at 250 mg QD (C1) + 150 mg QD (starting from C2), 28 days as a cycle.
* Control group: Patients will receive treatment with one of the following regimens, and the regimen will be selected by the investigator based on the patient's condition:

  * MEC regimen: etoposide injection 100 mg/m2, cytarabine injection 1000 mg/m2, mitoxantrone injection 8 mg/m2 QD IV for 5 consecutive days (Days 1-5).
  * FLAG ± Ida regimen: granulocyte colony stimulating factor (G-CSF) injection 300 mcg/m2 QD subcutaneous injection（SC） for 5 consecutive days (Days 1-5); fludarabine injection 30 mg/m2 QD IV for 5 consecutive days (Days 2-6); cytarabine injection 2000 mg/m2 QD IV for 5 consecutive days (Days 2-6); idarubicin injection 10 mg/m2 QD IV for 3 consecutive days (Days 2-4). This regimen can be given with or without Ida, which will be determined by the investigator based on the actual condition of the patient. After the completion of chemotherapy, the investigator will determine whether it is necessary to continue G-CSF administration. If necessary, G-CSF may be administered again until absolute neutrophil count (ANC) \> 0.5 × 109/L.
  * LoDAC: cytarabine injection 20 mg q12h SC or IV for 10 consecutive days (Days 1-10).
  * Azacitidine: azacitidine injection 75 mg/m2 QD SC or IV for 7 consecutive days (Days 1-7).

Phase of study:

The study phase includes a pre-screening period, a screening period, a treatment period, and a follow-up period \[including end-of-treatment (EOT) follow-up, EFS follow-up, and OS follow-up\].

Pre-screening period: The pre-screening period is defined as the period from signing the pre-screening ICF to obtaining test reports on IDH1 and IDH2 mutations. For patients without a previous report of IDH1 or IDH2 testing, specimens can be sent to the central laboratory for IDH1 and IDH2 mutation and other concomitant gene testing before screening and after signing the pre-screening ICF. Patients previously reported to be positive for IDH1/IDH2 mutation test can enter the screening period directly without pre-screening, if permitted by the investigator. Patients should not be enrolled until the test results are confirmed by the central laboratory.

The screening period is defined as the time from signing the main screening ICF until pre-dose on C1D1.

The treatment period is defined as the time from the first dose to EOT. EOT visit: Patients at EOT are required to return to the study site for an EOT follow-up visit within 30 (±7) days after the last dose of investigational product or before starting any other anti-tumor therapy, whichever occurs first.

EFS follow-up: Patients at EOT (except for PD/recurrence and lack of efficacy) will be retained in the study and enter the EFS follow-up stage. EFS follow-up will be conducted every 8 weeks from the day of entering the EFS follow-up stage until progression of disease/recurrence, death, withdrawal by the patient or his/her legal representative, loss to follow-up, or end of study (whichever occurs first). Subsequent new transplant conditioning regimens or new anti-tumor regimens should be recorded during the EFS follow-up period. \[According to the "Guidelines for Clinical Development of New Drugs for Acute Myeloid Leukemia" issued by the Center for Drug Evaluation (CDE), "lack of efficacy" is defined as failure to achieve CR or CRh/CR with incomplete hematologic recovery (CRi)/morphological leukemia-free status (MLFS)/partial response (PR) after 2 cycles of treatment under the protocol of the intensive chemotherapy group. In the reduced intensity chemotherapy group, if CR or CRh/CRi/MLFS/PR is not achieved after 180 days of treatment, it will be judged as lack of efficacy. "Lack of efficacy" in the test group is defined as failure to achieve CR or CRh/CRi/MLFS/PR from the day of HMPL-306 treatment until C5D1 (including C5D1 visit). Whether patients are considered "lack of efficacy" during the study will be determined by the investigator based on the actual clinical condition. For patients who are deemed as having experienced an event-free survival (EFS) event due to meeting the definition of "lack of efficacy" among EFS events, but who could still potentially benefit from continued treatment as judged by the investigator, they may continue to receive treatment after being fully informed (without changing the conclusion that an EFS event has occurred)\].

OS follow-up: After the end of EFS follow-up, patients will enter the overall survival (OS) follow-up stage. OS follow-ups will be conducted every 8 weeks from the day of OS follow-up until death, request for withdrawal from the study by the patient or her/his legal representative, loss to follow-up, or end of study (whichever occurs first).

End of study The two cohorts may vary in the time of end of study. The end of study for each cohort is defined as the number of target OS events for which the final analysis is observed in that cohort. The actual study duration for each cohort depends on the actual enrollment rate, dropout rate, and median OS of each group.

Efficacy assessment Efficacy assessment will be based on the European Leukemia Collaboration (ELN) 2022 criteria. Efficacy assessment will be conducted once every cycle during the first 6 treatment cycles (i.e., C2D1, C3D1, C4D1, C5D1, C6D1, and C7D1) and once every 2 cycles thereafter (i.e., C9D1, C11D1, C13D1,... ); efficacy evaluation will also be conducted at EOT follow-up and at each EFS follow-up.

Safety assessment All adverse events (AEs) will be graded as per the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), V5.0. AEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA). The number and frequency of treatment emergent adverse events (TEAEs) will be summarized by system organ class (SOC) and preferred term (PT).

In this study, all serious adverse events (SAEs) related to study procedures reported from the date of signing the informed consent form for pre-screening to the date of signing the master informed consent form will be collected; all SAEs need to be collected from the date of signing the master informed consent form to the date of the first dose; all AE/SAEs need to be collected from the first dose to 30 days after the last dose or the initiation of a new anti-tumor therapy, whichever occurs first; SAEs confirmed by investigators as having a reasonable possibility of correlation with the investigational product need to be collected 30 days after the last dose or after the initiation of a new anti-tumor therapy, whichever occurs earliest.

A Study to Evaluate HMPL-306 in Patients With IDH1- and IDH2-mutated Acute Myeloid Leukemia

A Multicenter, Randomized, Open-Label, Phase III Clinical Study to Evaluate the Efficacy and Safety of HMPL-306 vs. Salvage Chemotherapy Regimens in Patients With IDH1- and IDH2-mutated Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Proportion of patients who achieve a complete remission (CR)

Proportion of patients who achieve complete remission plus complete remission with partial hematologic recovery rate

Proportion of patients who achieve complete remission plus complete remission with incomplete hematologic recovery and partial hematologic recovery rate

Maximum Plasma concentration (Cmax) of drug

Trough plasma concentration (Ctrough) of drug

Duration of CR (DoCR), duration of CR + CRh, duration of CR + CRh + Cri

Number of participants with treatment-related adverse events, treatment-emergent adverse events, serious adverse events, adverse events leading to dose modification, adverse events leading to death as assessed by CTCAE v5.0

Quality of life (QoL), as measured by Family Reported Outcome Measure (Form-Item Health Survey)

Time to first CR (TTCR), time to first CR + CRh \[TT (CR + CRh)\], time to first CR + CRh + CRi \[TT (CR + CRi + CRh)\]

Hutchmed

Cholangiocarcinoma

Glioblastoma

Glioma

Astrocytoma

Oligodendroglioma

Bile Duct Cancer

IDH305

Novartis Pharmaceuticals

A Phase I study of IDH305 in patients with advanced malignancies that harbor IDH1R132 mutations.

A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations

A Phase I Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations

To estimate the maximum tolerated dose/recommended dose for expansion (MTD/RDE)

To characterize the safety and tolerability of IDH305

To assess any preliminary anti-tumor activity of IDH305

Hematologic Neoplasms

AG-120 administered continuously as a single agent dosed orally every day of a 28-day cycle.

AG-120 administered continuously as a single agent dosed orally every day of a 28-day cycle. Subjects may continue treatment with AG-120 until disease progression, development of other unacceptable toxicity or hematopoietic stem cell transplant.

Institut de Recherches Internationales Servier Clinical Studies Department

The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-120 in advanced hematologic malignancies that harbor an IDH1 mutation. The first portion of the study is a dose escalation phase where cohorts of patients will receive ascending oral doses of AG-120 to determine maximum tolerated dose (MTD) and/or the recommended Phase II dose. The second portion of the study is a dose expansion phase where four cohorts of patients will receive AG-120 to further evaluate the safety, tolerability, and clinical activity of the recommended Phase II dose. Additionally, the study includes a substudy evaluating the safety and tolerability, clinical activity, pharmacokinetics, and pharmacodynamics of AG-120 in subjects with relapsed or refractory myelodysplastic syndrome with an IDH1 mutation. Anticipated time on study treatment is until disease progression or unacceptable toxicity occurs.

Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

Descriptive statistics will be used to summarize PK parameters for each dose group and, where appropriate, for the entire population. Such parameters will include (but are not limited to) maximum concentration (Cmax), time to maximum concentration (Tmax), AUC, elimination half-life, and the fraction of drug excreted unchanged in the urine.

The potential relationship between plasma exposure of AG-120 and plasma, urine, or bone marrow 2-HG levels will be explored with descriptive and graphical methods.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation	NCT02632708	Newly Diagnosed... Untreated AML AML Arising Fro... AML Arising Fro... AML Arising Aft...	AG-120 AG-221 cytarabine daunorubicin idarubicin mitoxantrone etoposide	18 Years -	Servier
A Phase II Stydy of Bevacizumab Plus Erlotinib in Patients for Krebs Cycle Altered Cancer	NCT05904457	Solid Tumors Advanced Solid ... Metastatic Canc...	bevacizumab erlotinib	19 Years -	Asan Medical Center
Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation	NCT02632708	Newly Diagnosed... Untreated AML AML Arising Fro... AML Arising Fro... AML Arising Aft...	AG-120 AG-221 cytarabine daunorubicin idarubicin mitoxantrone etoposide	18 Years -	Servier
A Study to Evaluate HMPL-306 in Patients With IDH1- and IDH2-mutated Acute Myeloid Leukemia	NCT06387069	Acute Myeloid L...	HMPL-306 Regime... Salvage Chemoth...	18 Years -	Hutchmed
A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations	NCT02381886	Advanced Malign...	IDH305	18 Years -	Novartis
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation	NCT02074839	Relapsed or Ref... Untreated AML Other IDH1-muta... Myelodysplastic...	AG-120	18 Years -	Servier
A Phase II Stydy of Bevacizumab Plus Erlotinib in Patients for Krebs Cycle Altered Cancer	NCT05904457	Solid Tumors Advanced Solid ... Metastatic Canc...	bevacizumab erlotinib	19 Years -	Asan Medical Center
A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations	NCT02381886	Advanced Malign...	IDH305	18 Years -	Novartis

Spots Global Cancer Trial Database for idh

Every month we try and update this database with for idh cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for idh

Every month we try and update this database with for idh cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for idh cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.